BioNTech Files Patent Lawsuit Against Moderna Over Next-Generation COVID-19 Vaccine Technology
核心洞察
BioNTech filed a patent infringement lawsuit against Moderna in Delaware federal court, claiming the company's newly approved mNEXSPIKE (搜索) COVID-19 (搜索) vaccine violates proprietary messenger RNA (搜索) technology patents.
The disputed technology involves an advanced mRNA vaccine formula that enables lower dosage administration while maintaining effectiveness, originally developed by BioNTech and Pfizer for their Comirnaty vaccine.
This legal action represents the latest development in an ongoing patent war between the pharmaceutical giants, with mNEXSPIKE (搜索) expected to account for 55% of Moderna's COVID vaccine revenue through the 2025-26 respiratory virus season.
BioNTech has filed a patent infringement lawsuit against Moderna in Delaware federal court, alleging that Moderna's next-generation COVID-19 (搜索) vaccine mNEXSPIKE (搜索) violates proprietary messenger RNA (搜索) technology patents. The German biopharmaceutical company filed the case on Thursday, targeting technology that enables streamlined vaccine design with lower dosage requirements.
Patent Dispute Centers on Advanced mRNA Technology
The lawsuit focuses on BioNTech's patented technology for an advanced messenger RNA (搜索) vaccine formula that allows smaller doses to be administered to patients while maintaining effectiveness. According to court documents, BioNTech developed this innovation alongside partner Pfizer for their Comirnaty vaccine, and claims Moderna's mNEXSPIKE (搜索) uses this proprietary technology without permission.
mNEXSPIKE (搜索) received FDA approval in 2025 and represents Moderna's next-generation COVID-19 (搜索) vaccine offering. The lawsuit indicates that this vaccine is expected to account for 55% of Moderna's COVID vaccine revenue through the 2025-26 respiratory virus season, highlighting the significant commercial stakes involved in the patent dispute.
Escalating Legal Battle Between Vaccine Giants
This legal action represents the latest chapter in an ongoing patent war between the two pharmaceutical companies. Moderna previously filed its own lawsuit against BioNTech and Pfizer for patent infringement over Comirnaty in 2022, a case that remains unresolved in the courts.
The competing lawsuits are part of a broader trend across the biotechnology industry, where companies are pursuing legal claims seeking compensation for intellectual property used in the highly profitable COVID-19 (搜索) vaccines. These cases reflect the wave of patent lawsuits from biotech companies seeking royalties for technology used in the blockbuster vaccines.
Industry Context and Financial Impact
COVID vaccine revenues have dropped sharply since the height of the pandemic, when Moderna's Spikevax and Pfizer and BioNTech's Comirnaty earned the companies billions in revenue. Vaccine revenues in general have also slumped following U.S. President Donald Trump's appointment of vaccine skeptic Robert F. Kennedy Jr. as health secretary.
A Moderna spokesperson stated that the company would defend itself against BioNTech's case. BioNTech did not immediately respond to requests for comment on the new lawsuit, while Pfizer representatives, who are not named as defendants in this particular case, also declined to comment.